Retatrutide is the first triple-agonist — activating GLP-1, GIP and glucagon receptors. In Phase 3 trials, participants lost an average of 28.3% of their body weight. If Wegovy® or Zepbound® stopped working, this is the next-step conversation you've been looking for.
See If I Qualify →3-minute eligibility quiz · Reviewed by a licensed U.S. provider · $0 today
You didn't fail your medication.
You hit the ceiling of its mechanism.
Every GLP-1 medication works by activating receptors. When those receptors adapt, "more of the same drug" stops being the answer. Here's the math nobody explained to you:
1 receptor — GLP-1 only. The first breakthrough. For many, the first ceiling too.
2 receptors — GLP-1 + GIP. Better averages. Still plateaus for a huge share of users.
3 receptors — GLP-1 + GIP + glucagon. The first triple-agonist. A different pathway, not just a higher dose.
Glucagon is the lever the other two medications don't touch — it's tied to energy expenditure and fat oxidation. So instead of squeezing harder on a pathway your body already adapted to, retatrutide opens a second front: appetite signaling and how much energy your body burns. That's why plateaued GLP-1 users — people exactly like you — are the ones watching this molecule most closely.
Not a supplement. Not a "research chemical." A molecule with real Phase 3 trial data:
TRIUMPH program, once-weekly retatrutide. Individual results vary. Retatrutide is investigational and not yet FDA-approved.
Each generation of this medication class added a receptor — and the average results climbed with it:
| Medication | Receptors | Avg. Weight Loss* |
|---|---|---|
| Semaglutide | 1 (GLP-1) | ~15% |
| Tirzepatide | 2 (GLP-1 + GIP) | ~21% |
| Retatrutide | 3 (+ Glucagon) | up to 28.3% |
*Averages from respective clinical trial programs; not a head-to-head study. Your provider will tell you if — and how — a switch makes sense for your history.
You've seen the grey-market threads. The "rat" jokes. The PayPal accounts with different names. That's not a medical plan — that's a gamble. Here's the legitimate route:
Tell us your GLP-1 history — what you took, what dose, where you stalled. It costs $0 and takes less time than your morning injection routine.
A real clinician looks at your medication history, your plateau, and your contraindications. If a next-generation protocol isn't appropriate, they'll tell you — honestly.
Dosed correctly. Labeled correctly. Cold-shipped to your door. With provider follow-ups while you titrate — not a Telegram username that disappears after payment.
$0 today · No obligation · Answer in minutes, not weeks
"Down 61 lbs on Zepbound, then nothing for five months. My doctor shrugged and told me to cut more calories. The provider here actually looked at my history and explained WHY I stalled. Four months on the new protocol and I've broken through — 19 more pounds gone."
"I'll be honest — I was two clicks away from ordering from some overseas site at 1 a.m. The reviews all said 'don't get scammed, bro.' Instead I did the quiz, a provider reviewed me in a day, and everything came from a real pharmacy with real labels. That peace of mind alone was worth it."
"The food noise came back and I thought it was me — like I'd broken the miracle. Nobody told me receptors adapt. Having a clinician explain the mechanism, then actually have a next step ready? I felt hope again for the first time in a year."
No insurance battles. No six-week wait for a referral. No overseas roulette.
Takes ~3 minutes · Reviewed by a real clinician · Cancel anytime
If our provider determines a next-generation protocol isn't right for you, you pay nothing. Zero. You'll still walk away knowing exactly where you stand — and what your real options are.
Not yet — it's in Phase 3 trials, which is exactly why the data is so strong and so recent. Access today runs through licensed providers and legitimate pharmacy channels where legally permitted. What you should never do is source it from anonymous overseas vendors — unknown purity, unknown dosing, zero oversight. That's the whole reason this program exists.
Because it's not "more of the same." Semaglutide activates one receptor. Tirzepatide activates two. Retatrutide activates three — adding the glucagon pathway, which is tied to energy expenditure and fat oxidation. When your body adapts to one pathway, a different mechanism is a fundamentally different conversation than a dose increase.
The most common in trials were gastrointestinal — nausea, diarrhea, constipation — mostly during titration, similar to what you already know from GLP-1s. This is why the provider review and the guided titration plan matter: your starting dose is based on your current medication and history, not a guess from a forum.
Once weekly, same as the medications you're already used to. If you can handle your current injection routine, nothing about this is new — except the mechanism doing the work.
Then you pay $0 and lose three minutes. The provider will tell you honestly — and in many cases can point you to a better-fit option within the program. The only bad outcome here is staying stuck because you never asked.
Ask the threads — "im just trying to not get scammed lol" is the most common sentence in grey-market peptide communities for a reason. Unknown purity. Mislabeled doses. Payment channels designed so you can never get your money back. No clinician if something goes wrong. Cheap vials get very expensive when the dose is wrong. This program exists so you never have to roll those dice.
You already did the hard part — you proved you respond to this class of medication. Now there's a mechanism built for people who outgrew the first two generations. The only question is whether you ask about it this week… or six months from now, after another six months of stuck.
See If I Qualify — $0 Today →3-minute quiz · Licensed provider review · No prescription, no charge